Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
Neuro Oncol
.
2021 Aug 2;23(8):1415.
doi: 10.1093/neuonc/noaa115.
Authors
Martin van den Bent
,
Marica Eoli
,
Juan Manuel Sepulveda
,
Marion Smits
,
Annemiek Walenkamp
,
Jean-Sebastian Frenel
,
Enrico Franceschi
,
Paul M Clement
,
Olivier Chinot
,
Filip de Vos
,
Nicolas Whenham
,
Paul Sanghera
,
Michael Weller
,
H J Dubbink
,
Pim French
,
Jim Looman
,
Jyotirmoy Dey
,
Scott Krause
,
Pete Ansell
,
Sarah Nuyens
,
Maarten Spruyt
,
Joana Brilhante
,
Corneel Coens
,
Thierry Gorlia
,
Vassilis Golfinopoulos
PMID:
32609812
PMCID:
PMC8328008
DOI:
10.1093/neuonc/noaa115
No abstract available
Publication types
Published Erratum
Grants and funding
AbbVie